Phase II study of AMSA in lung cancer.
Cancer Treat Rep
; 65(7-8): 655-8, 1981.
Article
em En
| MEDLINE
| ID: mdl-6265083
ABSTRACT
Ninety-one assessable patients with advanced oat cell and non-oat cell carcinoma of the lung were given AMSA on an intermittent every-3-week schedule. Starting doses ranged from 55 to 120 mg/m2, depending on the presence and severity of hepatic dysfunction. Three partial responses (two squamous cell carcinomas, one adenocarcinoma) of short duration were documented. The major toxic effect was leukopenia (44%). AMSA does not appear to have sufficient antitumor activity to warrant further investigation in advanced lung cancer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aminoacridinas
/
Neoplasias Pulmonares
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Treat Rep
Ano de publicação:
1981
Tipo de documento:
Article